

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sincere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

COMPLETION OF ISSUE OF NEW SHARES UNDER THE 2021 RSU SCHEME

References are made to (i) the announcement of Sincere Pharmaceutical Group Limited (the “**Company**”) dated May 20, 2021 in relation to the adoption of the 2021 RSU Scheme; and (ii) the announcement of the Company dated May 11, 2022 in relation to, among others, the grant of Awards and issue of New Shares under the 2021 RSU Scheme (collectively, the “**Announcements**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as those defined in the Announcements.

The Board is pleased to announce that the Listing Committee of the Stock Exchange has granted the approval for the listing of, and permission to deal in, the New Shares. The condition precedent to the issue of the New Shares has been satisfied and the Company has, on May 25, 2022, issued a total of 6,776,000 new Shares to the Tricor Trustee to hold on trust for the Grantees.

The New Shares represent approximately 0.256% of the total number of Shares in issue as enlarged by the issue and allotment of the New Shares and the New Shares were issued under the General Mandate.

By order of the Board of
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, May 25, 2022

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.